Human papillomavirus vaccine - Oryx
Alternative Names: P16_37-63; p16INK4a peptide vaccine; p16INK4a-37-63; Vaccine p16; VicOryxLatest Information Update: 27 Sep 2021
Price :
$50 *
At a glance
- Originator University of Heidelberg
- Developer Oryx GmbH & Co
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cancer
Most Recent Events
- 03 Dec 2018 VicOryx is still in phase I/II trials for Cancer (Combination therapy; Late-stage disease) in Germany (Oryx GmbH & Co pipeline, November 2018)
- 01 May 2017 Oryx GmbH completes a phase I/IIa trial in Cancer (Late-stage disease, Combination therapy) in Germany (NCT02526316) (Oryx pipeline, August 2017)
- 07 Jan 2016 Human papillomavirus vaccine is available for licensing before Jan 2016. http://www.oryx-medicine.com